Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BASILIXIMAB Cause Off label use? 567 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 567 reports of Off label use have been filed in association with BASILIXIMAB (Simulect). This represents 8.3% of all adverse event reports for BASILIXIMAB.

567
Reports of Off label use with BASILIXIMAB
8.3%
of all BASILIXIMAB reports
155
Deaths
227
Hospitalizations

How Dangerous Is Off label use From BASILIXIMAB?

Of the 567 reports, 155 (27.3%) resulted in death, 227 (40.0%) required hospitalization, and 64 (11.3%) were considered life-threatening.

Is Off label use Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BASILIXIMAB. However, 567 reports have been filed with the FAERS database.

What Other Side Effects Does BASILIXIMAB Cause?

Cytomegalovirus infection (590) Drug ineffective (567) Transplant rejection (554) Kidney transplant rejection (456) Product use in unapproved indication (428) Pyrexia (323) Diarrhoea (314) Multiple organ dysfunction syndrome (298) Polyomavirus-associated nephropathy (298) Acute kidney injury (285)

What Other Drugs Cause Off label use?

RITUXIMAB (39,751) INFLIXIMAB (34,801) DENOSUMAB (34,612) METHOTREXATE (24,020) VEDOLIZUMAB (21,017) ETANERCEPT (20,178) TOCILIZUMAB (18,256) PREDNISONE (17,867) LENALIDOMIDE (17,017) ADALIMUMAB (16,417)

Which BASILIXIMAB Alternatives Have Lower Off label use Risk?

BASILIXIMAB vs BAYER GENUINE ASPIRIN ORIGINAL STRENGTH BASILIXIMAB vs BAZEDOXIFENE\ESTROGENS, CONJUGATED BASILIXIMAB vs BCG VACCINE BASILIXIMAB vs BEBTELOVIMAB BASILIXIMAB vs BECLOMETHASONE

Related Pages

BASILIXIMAB Full Profile All Off label use Reports All Drugs Causing Off label use BASILIXIMAB Demographics